findmyKOL
Clinical trialNCT04666740Active, not recruitingPhase 2Interventional

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

SponsorMemorial Sloan Kettering Cancer CenterEnrollment63Homologous Recombination Deficiency (HRD)Metastatic Pancreatic Ductal Adenocarcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study researchers think that combining the drugs pembrolizumab and olaparib (POLAR) may help people with this disease because pembrolizumab activates the immune system to fight cancer, and olaparib destroys cancer cells by preventing them from repairing damage to the genetic information that helps them survive and grow. The study researchers are doing this study to find out whether combining these drugs may be a more effective treatment for this cancer than taking olaparib alone.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Monmouth (all Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (all Protocol Activities)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (all Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (all Protocol Activities)

    Harrison, New York, United States

  • Memorial Sloan Kettering Basking Ridge (all Protocol Activities)

    New York, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (all Protocol Activities)

    Rockville Centre, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

OlaparibPembrolizumab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Dec 2020
Primary completion
31 Jan 2027
Completion
31 Jan 2027
Last update posted
18 Feb 2026
Registered enrollment
63
Registry id
NCT04666740
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.